683 Capital Management LLC Makes New $948,000 Investment in Assembly Biosciences, Inc. $ASMB

683 Capital Management LLC purchased a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,863 shares of the biopharmaceutical company’s stock, valued at approximately $948,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Farallon Capital Management LLC purchased a new stake in Assembly Biosciences in the third quarter worth about $31,426,000. RA Capital Management L.P. purchased a new stake in Assembly Biosciences in the third quarter worth about $26,122,000. Commodore Capital LP purchased a new stake in Assembly Biosciences in the third quarter worth about $25,600,000. Paradigm Biocapital Advisors LP purchased a new stake in Assembly Biosciences in the fourth quarter worth about $22,625,000. Finally, Vanguard Group Inc. increased its position in Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after buying an additional 248,287 shares in the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Wall Street Analysts Forecast Growth

ASMB has been the subject of a number of analyst reports. Mizuho set a $45.00 price target on Assembly Biosciences and gave the stock an “outperform” rating in a research report on Monday. Guggenheim restated a “buy” rating and issued a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research report on Monday, May 4th. Finally, Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $44.00.

Assembly Biosciences Trading Up 3.5%

Shares of Assembly Biosciences stock opened at $24.15 on Thursday. The stock has a 50 day moving average of $27.32 and a 200 day moving average of $29.15. Assembly Biosciences, Inc. has a 12 month low of $16.50 and a 12 month high of $39.71. The firm has a market cap of $383.74 million, a PE ratio of -219.53 and a beta of 1.07.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. The business had revenue of $8.21 million during the quarter, compared to analyst estimates of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. As a group, equities research analysts forecast that Assembly Biosciences, Inc. will post 1.9 earnings per share for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.